CY2020007I2 - Καινοτομες τρικυκλικες ενωσεις - Google Patents

Καινοτομες τρικυκλικες ενωσεις

Info

Publication number: CY2020007I2
Authority: CY; Cyprus
Prior art keywords: innovative; tricyclic compounds; tricyclic; compounds; innovative tricyclic
Prior art date: 2009-12-01

Application number

CY2020007C

Other languages

English (en)

Other versions

CY2020007I1 (el

Original Assignee

Abbvie Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-01

Filing date

2020-03-16

Publication date

2020-11-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2020007(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-03-16 Application filed by Abbvie Inc. filed Critical Abbvie Inc.

2020-05-29 Publication of CY2020007I1 publication Critical patent/CY2020007I1/el

2020-11-25 Publication of CY2020007I2 publication Critical patent/CY2020007I2/el

Links

150000001875 compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Transplantation (AREA)

CY2020007C 2009-12-01 2020-03-16 Καινοτομες τρικυκλικες ενωσεις CY2020007I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26556309P	2009-12-01	2009-12-01
US36411610P	2010-07-14	2010-07-14
PCT/US2010/058572 WO2011068881A1 (en)	2009-12-01	2010-12-01	Novel tricyclic compounds

Publications (2)

Publication Number	Publication Date
CY2020007I1 CY2020007I1 (el)	2020-05-29
CY2020007I2 true CY2020007I2 (el)	2020-11-25

Family

ID=44070404

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20171100817T CY1119175T1 (el)	2009-12-01	2017-07-31	Καινοτομες τρικυκλικες ενωσεις
CY2020007C CY2020007I2 (el)	2009-12-01	2020-03-16	Καινοτομες τρικυκλικες ενωσεις

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20171100817T CY1119175T1 (el)	2009-12-01	2017-07-31	Καινοτομες τρικυκλικες ενωσεις

Country Status (41)

Country	Link
US (5)	US8426411B2 (el)
EP (3)	EP3266786A1 (el)
JP (3)	JP5607174B2 (el)
KR (3)	KR20180101626A (el)
CN (4)	CN108774237A (el)
AR (1)	AR079234A1 (el)
AU (4)	AU2010326108C1 (el)
BR (1)	BR112012013349B1 (el)
CA (2)	CA2991896A1 (el)
CL (1)	CL2012001397A1 (el)
CO (1)	CO6561771A2 (el)
CR (2)	CR20170159A (el)
CY (2)	CY1119175T1 (el)
DK (1)	DK2506716T3 (el)
DO (2)	DOP2012000151A (el)
EC (1)	ECSP12011979A (el)
ES (1)	ES2637588T3 (el)
HK (1)	HK1256947A1 (el)
HR (1)	HRP20171175T1 (el)
HU (2)	HUE033099T2 (el)
IL (4)	IL220054A (el)
LT (2)	LT2506716T (el)
LU (1)	LUC00149I2 (el)
ME (1)	ME02800B (el)
MX (1)	MX346959B (el)
MY (1)	MY167076A (el)
NL (1)	NL301035I2 (el)
NO (1)	NO2020006I1 (el)
NZ (1)	NZ600161A (el)
PE (1)	PE20121336A1 (el)
PH (1)	PH12016501009A1 (el)
PL (1)	PL2506716T3 (el)
PT (1)	PT2506716T (el)
RS (1)	RS56317B1 (el)
RU (2)	RU2570416C9 (el)
SG (2)	SG10201407976UA (el)
SI (1)	SI2506716T1 (el)
TW (3)	TW201802091A (el)
UY (1)	UY33071A (el)
WO (1)	WO2011068881A1 (el)
ZA (1)	ZA201203999B (el)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201612182A (en)	2008-06-10	2016-04-01	Abbvie Inc	Novel tricyclic compounds
WO2010119875A1 (ja) *	2009-04-14	2010-10-21	アステラス製薬株式会社	縮合ピロロピリジン誘導体
CA2781010A1 (en) *	2009-12-01	2011-06-09	Abbott Laboratories	Novel tricyclic compounds
CA2991896A1 (en) *	2009-12-01	2011-06-09	Abbvie Inc.	Novel tricyclic compounds as protein kinase inhibitors
TW201129565A (en)	2010-01-12	2011-09-01	Hoffmann La Roche	Tricyclic heterocyclic compounds, compositions and methods of use thereof
BR112013024267A2 (pt) *	2011-03-22	2018-06-26	Advinus Therapeutics Ltd	compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos.
JP6278406B2 (ja)	2011-04-21	2018-02-14	オリゲニスゲーエムベーハーＯｒｉｇｅｎｉｓＧｍｂｈ	キナーゼ・インヒビターとしての複素環化合物
WO2013007765A1 (en) *	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Fused tricyclic compounds for use as inhibitors of janus kinases
MY166970A (en) *	2011-08-12	2018-07-26	Nissan Chemical Ind Ltd	Subtituted pyrrolo [2,3-h][1,6]naphthyridines and compositions thereof as jak inhibitors
US20130072470A1 (en) *	2011-09-21	2013-03-21	Abbvie Inc.	Novel tricyclic compounds
CN102516146B (zh) *	2011-11-24	2013-10-02	爱斯特（成都）生物制药有限公司	5位为氮的四元氮杂螺环衍生物及其制备方法和用途
US9593115B2 (en)	2012-09-21	2017-03-14	Advinus Therapeutics Ltd.	Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
WO2014060113A1 (en)	2012-10-19	2014-04-24	Origenis Gmbh	Novel kinase inhibitors
JP6248948B2 (ja) *	2013-02-08	2017-12-20	日産化学工業株式会社	３環性ピロロピリジン化合物及びｊａｋ阻害剤
PT2958921T (pt)	2013-02-22	2017-11-20	Pfizer	Derivados de pirrolo[2,3-d]pirimidina como inibidores de janus cinases (jak)
CA3012383C (en)	2013-02-28	2021-03-02	Teewinot Technologies Limited	Biosynthesis of cannabinoids
AU2014306759B2 (en)	2013-08-12	2018-04-26	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
WO2015061665A1 (en)	2013-10-24	2015-04-30	Abbvie Inc.	Jak1 selective inhibitor and uses thereof
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
US10172797B2 (en)	2013-12-17	2019-01-08	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
JP6726658B2 (ja) *	2014-04-11	2020-07-22	イェン、ユンYEN, Yun	ヒストン脱アセチル化酵素阻害剤
JP6561984B2 (ja)	2014-05-14	2019-08-21	日産化学株式会社	３環性化合物及びｊａｋ阻害剤
EP3169315B1 (en)	2014-07-17	2020-06-24	Pharmaceutical Manufacturing Research Services, Inc.	Immediate release abuse deterrent liquid fill dosage form
JP6585158B2 (ja)	2014-08-12	2019-10-02	ファイザー・インク	ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
JP6622793B2 (ja)	2014-08-25	2019-12-18	ティーウィノットテクノロジーズリミテッド	カンナビノイド化合物を同時作製する装置及び方法
AU2015336065A1 (en)	2014-10-20	2017-05-04	Pharmaceutical Manufacturing Research Services, Inc.	Extended release abuse deterrent liquid fill dosage form
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
CN116270646A (zh)	2015-10-16	2023-06-23	艾伯维公司	制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR112018014525A2 (pt)	2016-01-14	2018-12-11	Handok Inc	compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
EP3433615A1 (en)	2016-03-21	2019-01-30	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods for diagnosis and treatment of solar lentigo
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
UA125042C2 (uk)	2016-12-16	2021-12-29	Янссен Фармацевтика Нв	Малі молекули-інгібітори кіназ родини jak
EP3592353A1 (en)	2017-03-09	2020-01-15	AbbVie Inc.	Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en)	2017-03-09	2023-01-31	Abbvie Inc.	Methods of treating crohn's disease and ulcerative colitis
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US10364245B2 (en)	2017-06-07	2019-07-30	Chiesi Farmaceutici S.P.A.	Kinase inhibitors
WO2019057103A1 (zh) *	2017-09-21	2019-03-28	上海华汇拓医药科技有限公司	Jak激酶抑制剂及其制备方法和在医药领域的应用
US10508113B2 (en)	2018-03-12	2019-12-17	Abbvie Inc.	Inhibitors of tyrosine kinase 2 mediated signaling
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
WO2020043033A2 (zh) *	2018-08-31	2020-03-05	苏州鹏旭医药科技有限公司	一种乌帕替尼及其中间体的合成方法
CN110872250B (zh) *	2018-08-31	2023-01-10	苏州鹏旭医药科技有限公司	两种化合物及其制备方法和在合成乌西替尼中的用途
EP3856742B1 (en)	2018-11-01	2024-10-02	Lynk Pharmaceuticals Co. Ltd.	Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
CN111217819B (zh) *	2018-11-27	2021-05-14	杭州科巢生物科技有限公司	乌帕替尼的合成方法
EP3891151A1 (en)	2018-12-05	2021-10-13	LEK Pharmaceuticals d.d.	Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
WO2020115213A1 (en)	2018-12-07	2020-06-11	Lek Pharmaceuticals D.D.	Solvate of a selective jak1 inhibitor
CN109761885B (zh) *	2019-02-21	2020-06-26	北京悦康科创医药科技股份有限公司	一种阿加曲班异构体杂质的拆分方法
US20210380596A1 (en) *	2019-03-01	2021-12-09	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Upadacitinib crystal form and preparation method therefor and use thereof
AU2020232757A1 (en)	2019-03-05	2021-10-07	Incyte Corporation	JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
KR20210134738A (ko)	2019-03-14	2021-11-10	상하이 시너지 파마슈티컬 사이언시스 코., 엘티디.	Jak 억제제 및 그 제조방법과 의약분야에서의 응용
WO2020202183A1 (en)	2019-03-29	2020-10-08	Mylan Laboratories Limited	The process for the preparation of upadacitinib and its intermediates
CN111909160B (zh) *	2019-05-09	2024-05-28	苏州鹏旭医药科技有限公司	一种乌帕替尼盐类化合物及其制备方法
US20220305009A1 (en) *	2019-07-26	2022-09-29	Zhuhai Yufan Biotechnologies Co., Ltd	Irak4 kinase inhibitor and preparation method therefor
CN110938048B (zh) *	2019-12-02	2023-03-28	四川大学	路易酸催化的插入反应高效合成二氢呋喃衍生物
EP4077276A1 (en)	2019-12-19	2022-10-26	Curia Spain S.A.U.	Process and intermediates for the preparation of upadacitinib
CN111007184B (zh) *	2019-12-30	2023-05-16	天津天士力圣特制药有限公司	一种4-甲基哌嗪-1-甲酰氯盐酸盐含量的检测方法
WO2021176473A1 (en)	2020-03-05	2021-09-10	Mylan Laboratories Limited	A process for the preparation of upadacitinib and its intermediates
US11718622B2 (en)	2020-03-16	2023-08-08	Exelixis Inc.	Heterocyclic adenosine receptor antagonists
US20210371389A1 (en) *	2020-04-24	2021-12-02	Kansas Soybean Commission	One-step synthesis of soybean polyols
CN114206877B (zh) *	2020-06-05	2024-04-19	苏州科睿思制药有限公司	一种乌帕替尼的晶型及其制备方法和用途
CN114206878B (zh)	2020-07-08	2024-04-19	苏州科睿思制药有限公司	乌帕替尼的晶型及其制备方法和用途
WO2022044037A1 (en)	2020-08-24	2022-03-03	Mylan Laboratories Limited	An improved process for the preparation of upadacitinib intermediate
CA3192563A1 (en) *	2020-09-14	2022-03-17	Gilles Ouvry	Novel jak inhibitor compounds, method for synthesizing same and use thereof
CN112578034B (zh) *	2020-11-04	2022-02-11	广东众生睿创生物科技有限公司	一种手性胺小分子及其盐的质量控制方法
CN114790208B (zh) *	2021-01-26	2024-06-07	珠海宇繁生物科技有限责任公司	一种irak4激酶抑制剂及其制备方法
EP4319743A1 (en) *	2021-04-07	2024-02-14	Abbvie Inc.	Cocrystals of upadacitinib
CN113200967B (zh) *	2021-05-07	2022-05-24	中国人民解放军陆军军医大学	吲哚苯醌类化合物、其制备方法及其应用
CN113603693B (zh) *	2021-07-13	2022-08-26	陕西丽彩药业有限公司	一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法
CN114380837B (zh) *	2021-12-27	2023-06-30	上海邈金医药科技有限公司	一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
EP4215196A1 (en)	2022-01-24	2023-07-26	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
CN117285537B (zh) *	2023-11-27	2024-02-06	中节能万润股份有限公司	一种乌帕替尼的制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB716327A (en)	1951-09-05	1954-10-06	Ici Ltd	New heterocyclic compounds
US3663559A (en)	1969-12-03	1972-05-16	Union Carbide Corp	Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4053474A (en) *	1976-04-21	1977-10-11	E. R. Squibb & Sons, Inc.	Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US5605690A (en)	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5270316A (en)	1989-10-20	1993-12-14	Kyowa Hakko Kogyo Co., Ltd.	Condensed purine derivatives
HUT63170A (en)	1990-01-11	1993-07-28	Isis Pharmaceuticals Inc	Process and composition for detecting and modifying rna activity and gene expression
US6262241B1 (en)	1990-08-13	2001-07-17	Isis Pharmaceuticals, Inc.	Compound for detecting and modulating RNA activity and gene expression
DE69125394T2 (de)	1990-11-26	1997-08-21	Robert R. Omaha Nebr. Recker	Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
DE69231828T3 (de)	1991-03-18	2008-06-19	New York University	Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper
AU657986B2 (en)	1991-06-14	1995-03-30	Pharmacia & Upjohn Company	Imidazo(1,5-a)quinoxalines
US5212310A (en)	1991-12-19	1993-05-18	Neurogen Corporation	Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en)	1992-04-30	1993-11-30	Neurogen Corporation	Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en)	1992-08-27	1994-04-26	Neurogen Corporation	Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
DE69303494T2 (de)	1992-11-13	1997-01-16	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
SG43809A1 (en)	1993-02-26	1997-11-14	Schering Corp	2-benzyl-polycyclic guanine derivatives and process for preparing them
US5733905A (en)	1993-07-29	1998-03-31	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5736540A (en)	1993-07-29	1998-04-07	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en)	1994-09-20	1996-08-20	Talley; John J.	Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru)	1994-12-23	2000-10-27	Варнер-Ламберт Компани	Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5521173A (en)	1995-01-17	1996-05-28	American Home Products Corporation	Tricyclic benzazepine vasopressin antagonists
US5753648A (en)	1995-01-17	1998-05-19	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
US5763137A (en)	1995-08-04	1998-06-09	Agfa-Gevaert, N.V.	Method for making a lithographic printing plate
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
JP2002505330A (ja)	1998-03-04	2002-02-19	ブリストル−マイヤーズスクイブカンパニー	ヘテロシクロ−置換イミダゾピラジン・たんぱくチロシンキナーゼ抑制剤
US6448253B1 (en) *	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
CO5271670A1 (es)	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
JP4100865B2 (ja) *	1999-12-13	2008-06-11	エーザイ・アール・アンド・ディー・マネジメント株式会社	三環式縮合異項環化合物、その製造法およびその医薬
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP2004505942A (ja)	2000-08-07	2004-02-26	ニューロゲン　コーポレイション	Ｇａｂａａ受容体の配位子としての複素環式化合物
GB0115393D0 (en)	2001-06-23	2001-08-15	Aventis Pharma Ltd	Chemical compounds
GB0124299D0 (en)	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
ATE353013T1 (de)	2002-02-19	2007-02-15	Pfizer Italia Srl	Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
JP2006501243A (ja) *	2002-08-23	2006-01-12	カイロンコーポレイション	グリコーゲンシンターゼキナーゼ３のピロールベースのインヒビター
DE602004021558D1 (de) *	2003-01-17	2009-07-30	Warner Lambert Co	2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US7176214B2 (en)	2003-05-21	2007-02-13	Bristol-Myers Squibb Company	Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200524864A (en) *	2003-11-10	2005-08-01	Wyeth Corp	Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
MXPA06013250A (es) *	2004-05-14	2007-02-28	Abbott Lab	Inhibidores de quinasa como agentes terapeuticos.
AR049300A1 (es) *	2004-06-15	2006-07-12	Schering Corp	Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
ATE455777T1 (de)	2004-07-23	2010-02-15	Medicines Co Leipzig Gmbh	Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
CN101098872B (zh)	2004-11-22	2012-09-05	沃泰克斯药物股份有限公司	可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
DE602006014502D1 (de) *	2005-01-14	2010-07-08	Janssen Pharmaceutica Nv	Pyrazolopyrimidine als zellzyklus-kinasehemmer
ES2411975T3 (es) *	2005-01-14	2013-07-09	Janssen Pharmaceutica Nv	Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
US20060183758A1 (en)	2005-02-17	2006-08-17	Cb Research And Development, Inc.	Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
WO2006107771A2 (en) *	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
US7737279B2 (en) *	2005-05-10	2010-06-15	Bristol-Myers Squibb Company	1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en)	2005-05-12	2009-09-22	Cytopia Research Pty Ltd	Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CN101223168A (zh) *	2005-07-14	2008-07-16	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
US8163767B2 (en)	2005-07-14	2012-04-24	Astellas Pharma Inc.	Heterocyclic Janus Kinase 3 inhibitors
CN102127078A (zh) *	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
US8648116B2 (en)	2005-07-21	2014-02-11	Ardea Biosciences, Inc.	Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
MX2008002114A (es)	2005-07-21	2008-04-17	Ardea Biosciences Inc	Inhibidores de n-(arilamino)-sulfonamida de mek.
US7589101B2 (en) *	2005-08-16	2009-09-15	Irm Llc	Compounds and compositions as protein kinase inhibitors
CA2623541A1 (en)	2005-09-23	2007-03-29	Coley Pharmaceutical Group, Inc.	Method for 1h-imidazo[4,5-c]pyridines and analogs thereof
RU2008117298A (ru) *	2005-10-06	2009-11-20	Шеринг Корпорейшн (US)	Пиразолопиримидины как ингибиторы протеинкиназ
EP1954290B1 (en)	2005-11-22	2012-07-25	Merck Sharp & Dohme Corp.	Tricyclic compounds useful as inhibitors of kinases
WO2007079164A2 (en) *	2005-12-29	2007-07-12	Abbott Laboratories	Protein kinase inhibitors
US8546368B2 (en) *	2006-02-15	2013-10-01	Abbvie Inc.	Pyrazoloquinolones are potent PARP inhibitors
JP5386350B2 (ja)	2006-05-31	2014-01-15	タケダカリフォルニアインコーポレイテッド	グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
US8063225B2 (en)	2006-08-14	2011-11-22	Chembridge Corporation	Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2665214A1 (en)	2006-10-06	2008-05-29	Abbott Laboratories	Novel imidazothiazoles and imidazoxazoles
WO2008084861A1 (ja) *	2007-01-12	2008-07-17	Astellas Pharma Inc.	縮合ピリジン化合物
CA2676665A1 (en) *	2007-01-30	2008-08-07	Biogen Idec Ma Inc.	Modulators of mitotic kinases
WO2008112695A2 (en) *	2007-03-12	2008-09-18	Irm Llc	Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7691869B2 (en) *	2007-03-30	2010-04-06	King Pharmaceuticals Research And Development, Inc.	Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
CA2682304A1 (en)	2007-04-04	2008-10-16	F. Hoffmann-La Roche Ag	Microbial reduction of an acetoxyketone
US8188083B2 (en) *	2007-06-28	2012-05-29	Abbott Laboratories	Triazolopyridazines
KR20130066703A (ko) *	2008-02-06	2013-06-20	노파르티스 아게	피롤로［２,３ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도
ATE517107T1 (de)	2008-02-25	2011-08-15	Hoffmann La Roche	Pyrrolopyrazinkinaseinhibitoren
AU2009218607B2 (en)	2008-02-25	2014-02-13	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
JP5529049B2 (ja)	2008-02-25	2014-06-25	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼ阻害剤
WO2009108827A1 (en)	2008-02-29	2009-09-03	Wyeth	Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
TW201612182A (en) *	2008-06-10	2016-04-01	Abbvie Inc	Novel tricyclic compounds
CN102143746A (zh) *	2008-07-03	2011-08-03	埃克塞利希斯股份有限公司	Cdk 调节剂
WO2010119875A1 (ja)	2009-04-14	2010-10-21	アステラス製薬株式会社	縮合ピロロピリジン誘導体
US8361962B2 (en)	2009-07-27	2013-01-29	Roche Palo Alto Llc	Tricyclic inhibitors of JAK
CA2991896A1 (en) *	2009-12-01	2011-06-09	Abbvie Inc.	Novel tricyclic compounds as protein kinase inhibitors
CA2781010A1 (en)	2009-12-01	2011-06-09	Abbott Laboratories	Novel tricyclic compounds
WO2011156698A2 (en)	2010-06-11	2011-12-15	Abbott Laboratories	NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
US20120330012A1 (en)	2011-04-29	2012-12-27	Abbott Laboratories	Novel Tricyclic Compounds
US20130072470A1 (en)	2011-09-21	2013-03-21	Abbvie Inc.	Novel tricyclic compounds
WO2015061665A1 (en)	2013-10-24	2015-04-30	Abbvie Inc.	Jak1 selective inhibitor and uses thereof
CN116270646A (zh)	2015-10-16	2023-06-23	艾伯维公司	制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法

2010
- 2010-12-01 CA CA2991896A patent/CA2991896A1/en not_active Abandoned
- 2010-12-01 RS RS20170760A patent/RS56317B1/sr unknown
- 2010-12-01 CN CN201810448360.6A patent/CN108774237A/zh active Pending
- 2010-12-01 US US12/958,115 patent/US8426411B2/en not_active Ceased
- 2010-12-01 CN CN201410571754.2A patent/CN104370909B/zh active Active
- 2010-12-01 ME MEP-2017-167A patent/ME02800B/me unknown
- 2010-12-01 NZ NZ600161A patent/NZ600161A/en unknown
- 2010-12-01 AR ARP100104438A patent/AR079234A1/es active IP Right Grant
- 2010-12-01 EP EP17171010.6A patent/EP3266786A1/en not_active Withdrawn
- 2010-12-01 SG SG10201407976UA patent/SG10201407976UA/en unknown
- 2010-12-01 SI SI201031517T patent/SI2506716T1/sl unknown
- 2010-12-01 CN CN201080062920.6A patent/CN102711476B/zh active Active
- 2010-12-01 CA CA2781891A patent/CA2781891C/en active Active
- 2010-12-01 MY MYPI2012700314A patent/MY167076A/en unknown
- 2010-12-01 PL PL10835061T patent/PL2506716T3/pl unknown
- 2010-12-01 KR KR1020187025442A patent/KR20180101626A/ko active Application Filing
- 2010-12-01 UY UY0001033071A patent/UY33071A/es active IP Right Grant
- 2010-12-01 TW TW106122295A patent/TW201802091A/zh unknown
- 2010-12-01 JP JP2012542161A patent/JP5607174B2/ja active Active
- 2010-12-01 WO PCT/US2010/058572 patent/WO2011068881A1/en active Application Filing
- 2010-12-01 KR KR1020127017105A patent/KR101785257B1/ko active Protection Beyond IP Right Term
- 2010-12-01 RU RU2012127306A patent/RU2570416C9/ru not_active IP Right Cessation
- 2010-12-01 CN CN201810902092.0A patent/CN109053742B/zh active Active
- 2010-12-01 EP EP10835061.2A patent/EP2506716B1/en active Active
- 2010-12-01 ES ES10835061.2T patent/ES2637588T3/es active Active
- 2010-12-01 DK DK10835061.2T patent/DK2506716T3/en active
- 2010-12-01 BR BR112012013349A patent/BR112012013349B1/pt active IP Right Grant
- 2010-12-01 SG SG2012040465A patent/SG181472A1/en unknown
- 2010-12-01 TW TW099141754A patent/TWI500620B/zh active
- 2010-12-01 RU RU2015144809A patent/RU2711869C3/ru active Protection Beyond IP Right Term
- 2010-12-01 MX MX2012006311A patent/MX346959B/es active IP Right Grant
- 2010-12-01 CR CR20170159A patent/CR20170159A/es unknown
- 2010-12-01 LT LTEP10835061.2T patent/LT2506716T/lt unknown
- 2010-12-01 PT PT108350612T patent/PT2506716T/pt unknown
- 2010-12-01 EP EP21173353.0A patent/EP3950692A1/en active Pending
- 2010-12-01 TW TW104119191A patent/TWI600656B/zh not_active IP Right Cessation
- 2010-12-01 AU AU2010326108A patent/AU2010326108C1/en active Active
- 2010-12-01 HU HUE10835061A patent/HUE033099T2/en unknown
- 2010-12-01 KR KR1020177027803A patent/KR20170118230A/ko active Application Filing
- 2010-12-01 PE PE2012000745A patent/PE20121336A1/es active IP Right Grant
2012
- 2012-05-29 IL IL220054A patent/IL220054A/en active Protection Beyond IP Right Term
- 2012-05-30 DO DO2012000151A patent/DOP2012000151A/es unknown
- 2012-05-30 CL CL2012001397A patent/CL2012001397A1/es unknown
- 2012-05-31 ZA ZA2012/03999A patent/ZA201203999B/en unknown
- 2012-06-18 EC ECSP12011979 patent/ECSP12011979A/es unknown
- 2012-06-22 CO CO12105210A patent/CO6561771A2/es active IP Right Grant
- 2012-06-25 CR CR20120348A patent/CR20120348A/es unknown
2013
- 2013-02-07 US US13/761,501 patent/US20130216497A1/en not_active Abandoned
2014
- 2014-08-26 JP JP2014171336A patent/JP5985557B2/ja not_active Expired - Fee Related
2016
- 2016-01-14 DO DO2016000017A patent/DOP2016000017A/es unknown
- 2016-02-08 US US15/017,802 patent/US20160222020A1/en not_active Abandoned
- 2016-03-23 AU AU2016201825A patent/AU2016201825B2/en active Active
- 2016-05-27 PH PH12016501009A patent/PH12016501009A1/en unknown
- 2016-08-02 JP JP2016151711A patent/JP6298114B2/ja not_active Expired - Fee Related
- 2016-10-25 IL IL248466A patent/IL248466A/en active IP Right Review Request
2017
- 2017-03-01 US US15/446,102 patent/USRE47221E1/en active Active
- 2017-07-16 IL IL253516A patent/IL253516B/en unknown
- 2017-07-31 HR HRP20171175TT patent/HRP20171175T1/hr unknown
- 2017-07-31 CY CY20171100817T patent/CY1119175T1/el unknown
2018
- 2018-03-07 AU AU2018201663A patent/AU2018201663B2/en active Active
- 2018-09-13 IL IL261778A patent/IL261778A/en unknown
- 2018-12-14 HK HK18116085.2A patent/HK1256947A1/zh unknown
2019
- 2019-06-13 US US16/440,442 patent/US20210061813A1/en not_active Abandoned
2020
- 2020-02-26 AU AU2020201390A patent/AU2020201390A1/en not_active Abandoned
- 2020-03-09 LU LU00149C patent/LUC00149I2/fr unknown
- 2020-03-11 HU HUS2000008C patent/HUS000500I2/hu unknown
- 2020-03-11 NO NO2020006C patent/NO2020006I1/no unknown
- 2020-03-16 CY CY2020007C patent/CY2020007I2/el unknown
- 2020-03-17 NL NL301035C patent/NL301035I2/nl unknown
- 2020-03-17 LT LTPA2020505C patent/LTC2506716I2/lt unknown

Also Published As

Publication number	Publication date
EP2506716A4 (en)	2013-05-29
EP3950692A1 (en)	2022-02-09
US20160222020A1 (en)	2016-08-04
IL253516B (en)	2018-10-31
WO2011068881A1 (en)	2011-06-09
JP6298114B2 (ja)	2018-03-20
IL261778A (en)	2018-10-31
SG181472A1 (en)	2012-07-30
CO6561771A2 (es)	2012-11-15
HRP20171175T1 (hr)	2017-10-06
MX2012006311A (es)	2012-09-12
US20130216497A1 (en)	2013-08-22
IL220054A0 (en)	2012-07-31
PE20121336A1 (es)	2012-11-03
AU2020201390A1 (en)	2020-03-12
RU2711869C3 (ru)	2022-02-02
JP5985557B2 (ja)	2016-09-06
HUE033099T2 (en)	2017-11-28
CN102711476B (zh)	2014-12-03
US8426411B2 (en)	2013-04-23
IL253516A0 (en)	2017-09-28
AR079234A1 (es)	2012-01-04
IL220054A (en)	2016-10-31
AU2018201663B2 (en)	2020-03-05
US20210061813A1 (en)	2021-03-04
JP2017002068A (ja)	2017-01-05
CR20120348A (es)	2012-10-04
HUS2000008I1 (hu)	2020-03-30
CN102711476A (zh)	2012-10-03
SI2506716T1 (sl)	2017-10-30
RU2015144809A (ru)	2019-01-11
ZA201203999B (en)	2016-01-27
RU2570416C2 (ru)	2015-12-10
JP2015007094A (ja)	2015-01-15
CA2991896A1 (en)	2011-06-09
RU2570416C9 (ru)	2019-11-25
AU2010326108B2 (en)	2015-12-24
ECSP12011979A (es)	2012-07-31
PH12016501009A1 (en)	2017-10-18
EP3266786A1 (en)	2018-01-10
NZ600161A (en)	2014-08-29
TWI600656B (zh)	2017-10-01
LTC2506716I2 (lt)	2022-06-27
EP2506716B1 (en)	2017-05-17
MX346959B (es)	2017-04-06
LUC00149I1 (el)	2020-03-09
KR20140015151A (ko)	2014-02-06
AU2010326108A1 (en)	2012-06-14
DK2506716T3 (en)	2017-09-04
AU2016201825B2 (en)	2017-12-07
USRE47221E1 (en)	2019-02-05
ME02800B (me)	2018-01-20
LTPA2020505I1 (lt)	2020-04-10
CN109053742B (zh)	2021-06-15
PT2506716T (pt)	2017-08-24
MY167076A (en)	2018-08-10
NO2020006I1 (no)	2020-03-11
CA2781891C (en)	2018-02-13
US20110311474A1 (en)	2011-12-22
CN104370909B (zh)	2018-09-11
ES2637588T3 (es)	2017-10-13
RU2711869C2 (ru)	2020-01-22
NL301035I1 (nl)	2020-03-25
UY33071A (es)	2011-05-31
CR20170159A (es)	2017-06-26
BR112012013349A2 (pt)	2015-09-15
CY1119175T1 (el)	2018-02-14
KR20170118230A (ko)	2017-10-24
LUC00149I2 (el)	2021-02-15
CN109053742A (zh)	2018-12-21
BR112012013349B1 (pt)	2019-10-22
DOP2012000151A (es)	2012-09-30
CA2781891A1 (en)	2011-06-09
AU2010326108C1 (en)	2018-06-21
DOP2016000017A (es)	2016-03-31
EP2506716A1 (en)	2012-10-10
CY2020007I1 (el)	2020-05-29
JP2013512280A (ja)	2013-04-11
SG10201407976UA (en)	2015-01-29
AU2016201825A1 (en)	2016-04-14
CL2012001397A1 (es)	2012-09-14
KR20180101626A (ko)	2018-09-12
TW201546074A (zh)	2015-12-16
RU2015144809A3 (el)	2019-01-11
RU2012127306A (ru)	2014-01-10
TW201125869A (en)	2011-08-01
PL2506716T3 (pl)	2017-10-31
KR101785257B1 (ko)	2017-10-16
HUS000500I2 (hu)	2021-03-29
LT2506716T (lt)	2017-08-25
RS56317B1 (sr)	2017-12-29
JP5607174B2 (ja)	2014-10-15
IL248466A (en)	2017-07-31
NL301035I2 (nl)	2020-04-15
HK1256947A1 (zh)	2019-10-04
CN108774237A (zh)	2018-11-09
AU2018201663A1 (en)	2018-03-29
TW201802091A (zh)	2018-01-16
TWI500620B (zh)	2015-09-21
CN104370909A (zh)	2015-02-25

Publication	Publication Date	Title
CY2020007I2 (el)	2020-11-25	Καινοτομες τρικυκλικες ενωσεις
LTPA2017017I1 (lt)	2017-06-26	Tetraciklinis junginys
CY2016001I2 (el)	2018-01-10	Αντι-ιικες ενωσεις
SMT201600008B (it)	2016-02-25	Composti di piridazinone
BRPI0915374A2 (pt)	2015-08-04	Novos compostos tricíclicos
DK2427449T3 (da)	2013-04-22	Vinylindazolylforbindelser
BR112012006859A2 (pt)	2019-09-24	compostos
BRPI1013614A2 (pt)	2019-09-24	compostos substituídos de espiro-amida
BRPI1005525A2 (pt)	2016-02-23	compostos de azaazuleno
BRPI1008774A2 (pt)	2016-03-08	espiroamida substituída
BRPI1013246A2 (pt)	2016-04-05	derivados de benzofuralina
BR112012002828A2 (pt)	2015-10-13	derivados de 5-fluorpirimidinona
ECSP12011999A (es)	2012-07-31	Derivados benzamida sustituidos
BRPI1013868A2 (pt)	2016-04-05	composto diaciletilenodiamina
BRPI1013844A2 (pt)	2016-04-12	derivados de piridina-isoxazol
BR112012003868A2 (pt)	2015-09-01	Compostos orgânicos
UY33156A (es)	2011-07-29	Nuevos compuestos tienopirrol
BRPI1014454A2 (pt)	2016-04-05	derivados de isoxazol-pirazol
DK2387580T3 (da)	2014-10-13	Deoxyactagardinderivater
BR112012002810A2 (pt)	2015-09-15	derivados de n1-acil-5-fluoropirimidinona
BRPI0914538A2 (pt)	2015-12-15	derivados tricíclicos substituídos
BR112012009784A2 (pt)	2016-05-17	composto benzazepínico
DK2513115T3 (da)	2014-01-13	Tricycliske antibiotika
BR112012006693A2 (pt)	2015-09-08	combinação
BR112012004643A2 (pt)	2019-09-24	compostos antibióticos